Neglected Tropical Disease Treatment Market 2026
The Neglected Tropical Disease Treatment Market was valued at in and is anticipated to reach by , at a CAGR of 0.052 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Neglected Tropical Disease Treatment Market.
This report delivers a comprehensive overview of the Neglected Tropical Disease Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neglected Tropical Disease Treatment Market. The Neglected Tropical Disease Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Neglected Tropical Disease Treatment Market Scope:
By Disease Type
This report delivers a comprehensive overview of the Neglected Tropical Disease Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neglected Tropical Disease Treatment Market. The Neglected Tropical Disease Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Neglected Tropical Disease Treatment Market.
This report delivers a comprehensive overview of the Neglected Tropical Disease Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neglected Tropical Disease Treatment Market. The Neglected Tropical Disease Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Neglected Tropical Disease Treatment Market Scope:
By Disease Type
- Buruli Ulcer
- Chagas Disease
- Dengue and Chikungunya
- Dracunculiasis
- Echinococcosis
- Foodborne Trematodiases
- Human African Trypanosomiasis
- Leishmaniasis
- Leprosy
- Lymphatic Filariasis
- Mycetoma, Chromoblastomycosis
- Onchocerciasis
- Rabies
- Scabies
- Schistosomiasis
- Soil-transmitted Helminthiases
- Snakebite Envenoming
- Taeniasis/Cysticercosis
- Trachoma
- Yaws
- Medication
- Vaccines
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
- Cipla Limited
- AbbVie Inc.
- Takeda Pharmaceuticals
- Serum Institute of India
- Visterra Inc.(LIST NOT EXHAUSTIVE)
This report delivers a comprehensive overview of the Neglected Tropical Disease Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neglected Tropical Disease Treatment Market. The Neglected Tropical Disease Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing funding for drug discovery for the neglected tropical disease is expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. Lack of awareness are expected to get hampered in the forecast period.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Forces
5.2. Unmet Needs
5.3. Supply Chain
5.4. Pricing Analysis
5.5. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DISEASE TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type Segment
7.2. Buruli Ulcer*
7.2.1.1. Introduction
7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Chagas Disease
7.4. Dengue and Chikungunya
7.5. Dracunculiasis
7.6. Echinococcosis
7.7. Foodborne Trematodiases
7.8. Human African Trypanosomiasis
7.9. Leishmaniasis
7.10. Leprosy
7.11. Lymphatic Filariasis
7.12. Mycetoma, Chromoblastomycosis
7.13. Onchocerciasis
7.14. Rabies
7.15. Scabies
7.16. Schistosomiasis
7.17. Soil-transmitted Helminthiases
7.18. Snakebite Envenoming
7.19. Taeniasis/Cysticercosis
7.20. Trachoma
7.21. Yaws
8. BY TREATMENT TYPE
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type Segment
8.2. Medication*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Vaccines
9. BY DISTRIBUTION CHANNEL
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel Segment
9.2. Hospital pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Retail pharmacies
9.4. Online pharmacies
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. COMPETITIVE LANDSCAPE
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. COMPANY PROFILES
12.1. Bayer AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. F. Hoffmann-La Roche Ltd.
12.3. GlaxoSmithKline Plc
12.4. Novartis AG
12.5. Pfizer Inc.
12.6. Cipla Limited
12.7. AbbVie Inc.
12.8. Takeda Pharmaceuticals
12.9. Serum Institute of India
12.10. Visterra Inc.(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Applications
13.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing funding for drug discovery for the neglected tropical disease is expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. Lack of awareness are expected to get hampered in the forecast period.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Forces
5.2. Unmet Needs
5.3. Supply Chain
5.4. Pricing Analysis
5.5. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DISEASE TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type Segment
7.2. Buruli Ulcer*
7.2.1.1. Introduction
7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Chagas Disease
7.4. Dengue and Chikungunya
7.5. Dracunculiasis
7.6. Echinococcosis
7.7. Foodborne Trematodiases
7.8. Human African Trypanosomiasis
7.9. Leishmaniasis
7.10. Leprosy
7.11. Lymphatic Filariasis
7.12. Mycetoma, Chromoblastomycosis
7.13. Onchocerciasis
7.14. Rabies
7.15. Scabies
7.16. Schistosomiasis
7.17. Soil-transmitted Helminthiases
7.18. Snakebite Envenoming
7.19. Taeniasis/Cysticercosis
7.20. Trachoma
7.21. Yaws
8. BY TREATMENT TYPE
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type Segment
8.2. Medication*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Vaccines
9. BY DISTRIBUTION CHANNEL
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel Segment
9.2. Hospital pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Retail pharmacies
9.4. Online pharmacies
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. COMPETITIVE LANDSCAPE
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. COMPANY PROFILES
12.1. Bayer AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. F. Hoffmann-La Roche Ltd.
12.3. GlaxoSmithKline Plc
12.4. Novartis AG
12.5. Pfizer Inc.
12.6. Cipla Limited
12.7. AbbVie Inc.
12.8. Takeda Pharmaceuticals
12.9. Serum Institute of India
12.10. Visterra Inc.(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Applications
13.3. Contact Us
